PPI use linked to significantly worse progression-free, overall survival in advanced urothelial cancer.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
The purpose of this trial was to determine if suppression of MDSCs with acalabrutinib could enhance pembrolizumab activity safely in this population.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.
The 20-year mortality rate among patients with muscle-invasive bladder cancer is 71%, according to a study of Swedish patients. Investigators who analyzed a large population-based cohort of patients with bladder cancer that had more than 20 years of follow-up found that muscle-invasive bladder cancer (MIBC) results in a high risk of cancer-specific death, according to…
The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Genome-wide association studies have revealed over 180 SNPs associated with increased breast cancer risk.
A team of investigators from the University of Texas MD Anderson Cancer Center assessed whether a relationship exists between hepatitis C virus infection and common genitourinary cancers, such as kidney and prostate cancer.
The new guidance aims to support urologists and other clinicians in providing evidence-based care to their patients.